Latest Breaking News On - Summary of program - Page 3 : vimarsana.com

Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates Read full article Oops! SARS-CoV-2 Variant Booster Program Update : Single booster dose of 50 µg of mRNA-1273 or mRNA-1273.351 increased neutralizing titers against SARS-CoV-2 and two Variants of Concern (B.1.351, P.1) in previously vaccinated clinical trial participants TeenCOVE Study Update : Initial analysis of the Phase 2/3 TeenCOVE study of mRNA-1273 showed vaccine efficacy against COVID-19 of 96%; mRNA-1273 was generally well tolerated with no serious safety concerns identified to date 2021 and 2022 Vaccine Manufacturing: Company increased its 2021 supply forecast to between 800 million and 1 billion doses; Company making investments to increase global supply for COVID-19 Vaccine to up to 3 billion doses in 2022

United statesUnited kingdomSouth africaRepublic of south africaLavina talukdarIntratumoral immunoColleen husseyUs department of defenseMost influential companiesResearch developmentWorld most innovative companiesCoalition for epidemic preparedness innovationsDevelopment expensesMerck co incModerna incCompany recognition